Why Macquarie expects this dividend paying ASX 300 stock to leap 19%

Macquarie forecasts a strong year ahead for this ASX 300 dividend stock.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Bega Cheese Ltd shares have outperformed the ASX 300 Index over the past year and offer a 2.1% fully franked dividend yield.
  • Macquarie Group highlights Bega's potential for strong growth in dairy snacking products, driven by health and wellness trends, positioning it to excel in the underpenetrated morning snack market.
  • Bega Cheese aims to surpass a $250 million EBITDA target by FY 2028, with Macquarie raising its 12-month target price to $6.80.

The S&P/ASX 300 Index (ASX: XKO) stock, Bega Cheese Ltd (ASX: BGA), is marching higher today.

Bega Cheese shares closed yesterday, trading for $5.69. In early afternoon trade on Wednesday, shares are changing hands for $5.74, up 0.9%.

For some context, the ASX 300 is up 0.2% at this same time.

Taking a step back, Bega Cheese has also modestly outperformed over the past year, with shares up 8.4% compared to the 7.3% one-year gains delivered by the index.

Atop those capital gains, the ASX 300 stock also offers a 2.1% fully franked dividend yield.

And looking to the year ahead, the team at Macquarie Group Ltd (ASX: MQG) expects investors will see both higher dividends and a significantly higher share price from Bega Cheese.

Here's why.

Three cows jumping over a field of grass.

Image source: Getty Images

ASX 300 stock tipped to outperform

At the company's annual general meeting (AGM), held on 27 October, Bega Cheese CEO Pete Findlay noted, "Dairy continues to be a powerful vehicle for delivering daily health and wellness outcomes, and we are well-positioned to lead in that space."

Running the numbers on the ASX 300 stock in a new report released today, Macquarie highlighted the growth potential for dairy snacking products.

According to the broker:

Health/wellness trends are driving a high-single to low-double-digit sales CAGR globally in sub-categories, including high protein; no/low sugar; gut health; energy. In AU, dairy snacking products – particularly yoghurt – are delivering double-digit unit growth, with consumers preferring 'better-for-you' options over traditional snacking categories such as confectionery and soft drinks (low- to mid-single-digit unit growth).

Snacking in AU is under-penetrated in the morning daypart, rel. to global benchmarks (US and EU). Yoghurt & milk-based beverages (MBB) well placed to benefit from greater morning daypart snacking, driven by NPD through BGA's fast second-mover advantage.

Macquarie also noted the benefits of Bega Cheese's high market share when it comes to gaining the required shelf space and promotional campaigns with major customers, including supermarkets and convenience store operators.

On the earnings outlook, the ASX 300 stock is targeting significant growth.

According to Bega Cheese's Findlay:

We believe we are on track to exceed our EBITDA [earnings before interest taxes, depreciation and amortisation] target of $250 million by FY 2028. We are pleased to provide guidance for FY 2026 with a normalised EBITDA range of $215 million to $220 million, further evidence of our strategic momentum and delivery capability.

Macquarie said it is "gaining comfort" in Bega Cheese's revenue outlook.

"With BGA's key categories in a growing TAM, we believe this should give the market increasing confidence in BGA's ability to deliver sustained sales growth and exceed $250m+ in EBITDA by FY28E (MQe & VA cons ~$260m)," the broker said.

Connecting the dots, Macquarie raised its 12-month target price on the ASX 300 stock to $6.80 a share (up from the prior $6.60 a share).

That represents a potential upside of 18.5% from current levels. And it doesn't include those upcoming dividends.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Buy, hold, and sell ratings written on signs on a wooden pole.
Broker Notes

Down 65%! Are WiseTech shares now a bargain buy?

A leading expert provides his forecast for WiseTech’s struggling shares.

Read more »

Happy young couple doing road trip in tropical city.
Broker Notes

Are CAR Group shares a buy, hold or sell after rocketing 10% on results?

This stock is set to keep rebounding.

Read more »

Man lying down on sofa and trading on his laptop.
Broker Notes

2 ASX 200 stocks Morgans rates as a buy right now 

These two stocks offer significant upside.

Read more »

A woman in a red dress holding up a red graph.
Broker Notes

2 ASX shares to buy for returns better than 33%

These companies are primed for growth, Morgans says.

Read more »

A woman smiles at the outlook she sees through binoculars.
Broker Notes

Buy, hold, sell: Newmont, Stockland, NAB shares

Let's check out some new expert recommendations.

Read more »

Red sell button on an Apple keyboard.
Broker Notes

Sell alert! Why this expert is calling time on Whitehaven and Beach Energy shares

A leading analyst forecasts mounting headwinds for Whitehaven and Beach Energy shares. But why?

Read more »

A group of stockbrokers sit in a room with several computer screens in front of them as they discuss the Zip share price and Zip's merger with Sezzle
Broker Notes

Buy, hold, sell: WiseTech, Whitehaven, AMP shares

Let's start the week with some fresh ratings from the experts. 

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Broker Notes

How high does Macquarie think Resmed shares will go?

The hearing device company looks undervalued, according to the Macquarie team.

Read more »